Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 22

References for PMC Articles for PubMed (Select 20215447)

1.

Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study.

Khalangot M, Tronko M, Kravchenko V, Kovtun V.

Diabetes Res Clin Pract. 2009 Dec;86(3):247-53. doi: 10.1016/j.diabres.2009.09.008. Epub 2009 Sep 30.

PMID:
19796836
2.

Sulfonylureas and prognosis after myocardial infarction in patients with diabetes: a population-based follow-up study.

Horsdal HT, Johnsen SP, Søndergaard F, Jacobsen J, Thomsen RW, Schmitz O, Sørensen HT, Rungby J.

Diabetes Metab Res Rev. 2009 Sep;25(6):515-22. doi: 10.1002/dmrr.971.

PMID:
19459168
3.

The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis.

Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, Atreja A, Zimmerman RS.

Acta Diabetol. 2009 Jun;46(2):145-54. doi: 10.1007/s00592-008-0090-3. Epub 2009 Feb 5.

PMID:
19194648
4.

SUR receptor activity vs. incidence of hypoglycaemia and cardiovascular mortality with sulphonylurea therapy for diabetics.

Tayek J.

Diabetes Obes Metab. 2008 Nov;10(11):1128-9; author reply 1129-30. doi: 10.1111/j.1463-1326.2008.00928.x. Epub 2008 Jul 29. No abstract available.

PMID:
18671799
5.

No differences in mortality between users of pancreatic-specific and non-pancreatic-specific sulphonylureas: a cohort analysis.

Evans JM, Ogston SA, Reimann F, Gribble FM, Morris AD, Pearson ER.

Diabetes Obes Metab. 2008 Apr;10(4):350-2. Epub 2007 Dec 17.

PMID:
18093208
6.

A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin.

Gangji AS, Cukierman T, Gerstein HC, Goldsmith CH, Clase CM.

Diabetes Care. 2007 Feb;30(2):389-94.

PMID:
17259518
7.

Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin.

Evans JM, Ogston SA, Emslie-Smith A, Morris AD.

Diabetologia. 2006 May;49(5):930-6. Epub 2006 Mar 9.

PMID:
16525843
8.

Effects of glimepiride and glyburide on glucose counterregulation and recovery from hypoglycemia.

Szoke E, Gosmanov NR, Sinkin JC, Nihalani A, Fender AB, Cryer PE, Meyer C, Gerich JE.

Metabolism. 2006 Jan;55(1):78-83.

PMID:
16324923
9.

Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes.

Johnson JA, Simpson SH, Toth EL, Majumdar SR.

Diabet Med. 2005 Apr;22(4):497-502.

PMID:
15787679
10.

Sulphonylurea action revisited: the post-cloning era.

Gribble FM, Reimann F.

Diabetologia. 2003 Jul;46(7):875-91. Epub 2003 Jun 18. Review.

PMID:
12819907
11.

Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes.

Johnson JA, Majumdar SR, Simpson SH, Toth EL.

Diabetes Care. 2002 Dec;25(12):2244-8.

PMID:
12453968
12.

Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide.

Mocanu MM, Maddock HL, Baxter GF, Lawrence CL, Standen NB, Yellon DM.

Circulation. 2001 Jun 26;103(25):3111-6.

13.
14.

ATP-sensitive K+ channels and insulin secretion: their role in health and disease.

Ashcroft FM, Gribble FM.

Diabetologia. 1999 Aug;42(8):903-19. Review. No abstract available.

PMID:
10491749
15.

Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide.

Klepzig H, Kober G, Matter C, Luus H, Schneider H, Boedeker KH, Kiowski W, Amann FW, Gruber D, Harris S, Burger W.

Eur Heart J. 1999 Mar;20(6):439-46.

17.

Tissue specificity of sulfonylureas: studies on cloned cardiac and beta-cell K(ATP) channels.

Gribble FM, Tucker SJ, Seino S, Ashcroft FM.

Diabetes. 1998 Sep;47(9):1412-8.

PMID:
9726229
18.

Ischemic preconditioning during coronary angioplasty is prevented by glibenclamide, a selective ATP-sensitive K+ channel blocker.

Tomai F, Crea F, Gaspardone A, Versaci F, De Paulis R, Penta de Peppo A, Chiariello L, Gioffrè PA.

Circulation. 1994 Aug;90(2):700-5.

PMID:
8044938
19.

Glibenclamide is exceptional among hypoglycaemic sulphonylureas in accumulating progressively in beta-cell-rich pancreatic islets.

Hellman B, Sehlin J, Täljedal IB.

Acta Endocrinol (Copenh). 1984 Mar;105(3):385-90.

PMID:
6230850
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk